Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1643 1645 1646
This examiner grants 44% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17473401 | TREATMENT OF CANCER WITH HER2XCD3 BISPECIFIC ANTIBODIES IN COMBINATION WITH ANTI-HER2 MAB | Final Rejection | Genentech, Inc. |
| 18096167 | PSEUDOTYPED VIRUSES CONFIGURED TO EXPRESS CAR IN T-CELLS | Non-Final OA | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 17432868 | COMBINATION THERAPIES OF EGFRVIII CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | Final Rejection | Novartis AG |
| 18561506 | EGFR TARGETING FC ANTIGEN BINDING FRAGMENT-DRUG CONJUGATES | Non-Final OA | MERCK PATENT GMBH |
| 18548677 | T-CELLS FOR ANTI-HIV CAR-T THERAPY AND METHODS OF USE | Non-Final OA | City of Hope |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy